CareDX Lab Solutions Inc. Allo Seq Tx17 Next Generation Sequencing (NGS) Reagent Kits
ID: 25-000009Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/6c6ef7ffc3524c43ab142ac7315b5d95/view
Timeline
    Description

    The National Institutes of Health (NIH) intends to issue a sole source firm fixed-price purchase order to CareDx Lab Solutions Inc. for the procurement of Allo Seq Tx17 Next Generation Sequencing (NGS) reagent kits. This acquisition aims to secure a one-year supply of NGS reagents necessary for the Human Leukocyte Antigen (HLA) Laboratory within the Department of Transfusion Medicine, ensuring adequate stock for patient testing through quarterly shipments scheduled from November 2024 to August 2025. The HLA Laboratory plays a critical role in providing diagnostic testing and consultations for transplant eligibility, maintaining accreditation, and engaging in research for new diagnostic tests. Interested parties may submit their capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by October 30, 2024, at 6:30 AM EST, as this is not a request for proposals.

    Point(s) of Contact
    Shasheshe Goolsby
    (301) 827-4879
    shasheshe.goolsby@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Qiagen LLC DNA Isolation Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure DNA Isolation Kits from Qiagen LLC on a sole source basis. The acquisition aims to supply the Human Leukocyte Antigen (HLA) Lab with essential testing kits that have been rigorously tested to ensure high-quality DNA samples for critical patient testing. These kits are vital for HLA typing, particularly for critically ill patients, as they directly impact the turnaround time for results necessary for lifesaving transplants. Interested parties may submit their capability statements to Shasheshe Goolsby at shasheshe.goolsby@nih.gov by October 31, 2024, at 6:30 AM EST, as this is not a request for proposals.
    cDNA-PCR Sequencing Kits for long-read sequencing.
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking information from qualified sources regarding the availability of cDNA-PCR sequencing kits for long-read sequencing, as part of a Sources Sought notice. The primary objective is to procure PromethION flow cells and sequencing kits that are compatible with the Oxford Nanopore PromethION device, which is essential for high-throughput sequencing in research on Alzheimer’s disease and related dementias. These consumables will facilitate the analysis of DNA and RNA samples, aiding in the identification of potential therapeutic targets and biomarkers for Alzheimer's disease. Interested companies must submit their capability statements by October 28, 2024, at 5 PM Eastern Time, to Iris Merscher at iris.merscher@nih.gov, ensuring that all submissions adhere to the specified guidelines and page limits.
    Title: Global Life Sciences Sepax Cell Separation Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a firm fixed-price contract for the procurement of Global Life Sciences Sepax Cell Separation Kits and Ficoll Paque Premium reagents. The NIH's Department of Transfusion Medicine requires these items to support the manufacturing of cell-based therapies for patients with advanced metastatic cancer, utilizing the Sepax C-Pro Cell Processing Instruments. This acquisition is being conducted under the Simplified Acquisition Procedures, allowing for a sole-source award to Cytiva-Global Life Sciences Solutions USA LLC, with capability statements due by November 3, 2024, at 12:00 PM EST. Interested parties can direct inquiries to Sheri Eiri at sheri.eiri@nih.gov.
    Maintenance Service for two (2) Illumina NextSeq™ 1000 Sequencers
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to Illumina, Inc. for maintenance services on two Illumina NextSeq™ 1000 Sequencers. The contract will cover comprehensive support, including parts, labor, travel, and technical assistance, essential for high-throughput next-generation sequencing used in diagnosing inherited immune disorders. This acquisition is critical as Illumina is the sole manufacturer with the necessary components and expertise to maintain the equipment to its original specifications. Interested parties capable of providing similar services may submit a capability statement to Kimala Winfield at kimala.winfield@nih.gov or Malinda Dehner at dehnerm@cc.nih.gov, with submissions due by the specified deadline.
    MAINTENANCE AND REPAIR SERVICE AGREEMENT FOR NEXTSEQ 2000 (S/N: VH74007)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to negotiate a maintenance and repair service agreement for the Illumina NextSeq 2000 system, serial number VH74007. The contract will cover a 12-month support plan, including full maintenance for parts, labor, and travel, as well as preventative maintenance inspections, remote technical support, and software updates. This service is crucial for the Laboratory of Parasitic Diseases to ensure the operational efficiency of their sequencing equipment. Interested vendors must submit their capability statements and relevant documentation by 12:00 PM EST on November 15, 2024, via the NIH electronic Simplified Acquisition Submission System (eSASS), with all inquiries directed to Mildred Moss at mildred.moss@nih.gov or Tonia Alexander at talexander@niaid.nih.gov.
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits
    Active
    Health And Human Services, Department Of
    Notice of Intent BD Rhapsody Single-Cell Analysis Reagent Kits The Department of Health and Human Services, Department of, National Institutes of Health, is planning to procure BD Rhapsody Single-Cell Analysis Reagent Kits. These kits are used for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy, and gene therapy conducted in the Clinical Center at the NIH. The procurement includes a standing order for multi-type sequencing kits and reagents with a short shelf life. The contractor will be responsible for shipping the sufficient reagents and kits following the scheduled delivery dates. The shelf life of the sequencing reagents should be at least 3 months, and the shelf life of library generation kits should be at least 6 months. The contractor is also required to provide technical support for all kits and reagents at no additional cost. The period of performance for this procurement is from 5/1/2024 to 8/30/2024. The delivery schedule is overnight delivery Monday through Thursday to the Center for Cellular Engineering (CCE) at NIH/CC in Bethesda, MD. The vendor will be responsible for ensuring the safe transport of cryopreserved patient cells and maintaining the temperature and other parameters during the shipment of reagents and kits. The contractor will be paid per product delivered and is required to provide hard copies of proofs of each product delivered. Interested parties can submit their capabilities to the Office of Purchasing and Contracts by May 1st, 9:00 AM EST. Please note that this is not a request for proposal.
    NextSeq 2000 Silver Support Plan
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to procure a NextSeq 2000 Silver Support Plan from Illumina, Inc. This procurement is essential for maintaining high throughput sequencing capabilities that are critical for research into immune responses against infectious diseases, particularly through RNA sequencing methods. The support plan includes comprehensive service coverage, preventive maintenance, remote technical support, and timely on-site response during the performance period from November 1, 2024, to July 4, 2025. Interested parties must submit capability statements by October 28, 2024, to Angela Puddy at angela.puddy@nih.gov, as this is not a request for proposals and the Government retains discretion regarding competition for this requirement.
    Assay Kits for Lumipulse instrument
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking information from qualified sources regarding the availability of assay kits for the Lumipulse G1200 instrument, which is essential for conducting assays related to Alzheimer's disease biomarkers. The procurement aims to acquire state-of-the-art assay kits for quantifying serum/plasma levels of abeta42, abeta40, and pTau 217, which will be utilized in ongoing research involving stored specimens from the Baltimore Longitudinal Study of Aging (BLSA). Interested vendors are encouraged to submit capability statements detailing their ability to meet the project requirements, including manufacturing details and company qualifications, by October 28, 2024, at 5 PM Eastern Time, to Iris Merscher at iris.merscher@nih.gov. This notice serves as a Sources Sought announcement and does not constitute a solicitation for proposals or quotes.
    Sources Sought-BioFire Reagents and Test Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is conducting a Sources Sought announcement to identify potential qualified small businesses capable of supplying BioFire Defense reagents and test kits. The NIH's Department of Laboratory Medicine requires these reagents for their BioFire FilmArray analyzers, which are essential for the rapid detection of infectious agents from clinical samples, thereby facilitating timely treatment. Interested vendors must submit their company information, including a capability statement, by 12:00 PM EST on November 7, 2024, to Sheri Eiri at sheri.eiri@nih.gov, as the government will not reimburse any costs associated with this request.
    Reagent Generation for Bioanalytical Method Development on Biologics
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified sources for a potential contract focused on reagent generation for bioanalytical method development related to biologics. The primary objective is to obtain information on the availability and capability of companies to generate and deliver reagents, including anti-drug antibodies, that support the quantification of novel biologic drugs in various biological matrices. This initiative is crucial for advancing drug development processes and improving success rates in preclinical stages, with the Therapeutic Development Branch (TDB) at NIH playing a pivotal role in moving therapeutic candidates through the drug development pipeline. Interested parties must submit their capability statements by November 8, 2024, to Nick Niefeld at nick.niefeld@nih.gov, referencing sources sought notice number 75N95025R00007.